The global chimeric antigen receptor (CAR) T-cell therapy market garnered a market value of US$ 2.54 billion in 2022. The market is expected to accumulate a market value of US$ 3.5 billion by 2023, and will eventually reach US$ 6.82 billion by registering a CAGR of 6.9% in the forecast period 2023 to 2033. The growth of the chimeric antigen receptor (CAR) T-Cell therapy market can be attributed to technological advancements and demand for personalized medicines. The market for chimeric antigen receptor (CAR) T-Cell therapy registered a CAGR of 7% in the historical period 2018 to 2022.
Chimeric Antigen Receptor (CAR) T-cell therapy is a type of cancer treatment that uses a patient's own immune system to fight cancer. It is a type of immunotherapy that involves modifying a patient's T cells (a type of white blood cell) to recognize and attack cancer cells.
The CAR T-cell therapy process involves collecting a patient's T cells, genetically modifying them to express a CAR on their surface, and then reinfusing the modified cells back into the patient's bloodstream. The CAR is designed to recognize and bind to a specific protein on the surface of cancer cells, which triggers the T cells to attack and destroy the cancer cells.
Report Attribute
Details
Expected Market Value (2023)
US$ 3.5 billion
Anticipated Forecast Value (2033)
US$ 6.82 billion
Projected Growth Rate (2023 to 2033)
6.9% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Chimeric antigen receptor (CAR) T-Cell therapy Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Chimeric antigen receptor (CAR) T-Cell therapy reflected a value CAGR of 7% during the historical period, 2018 to 2022. The growth of the market can be attributed to several factors, including the increasing prevalence of cancer, the growing demand for personalized and targeted therapies, and the increasing investments in research and development of CAR T-cell therapies. In addition, the approval of several CAR T-cell therapies by regulatory agencies, such as the US FDA, has also boosted market growth.
Several companies are actively involved in the development and commercialization of CAR T-cell therapies, including Novartis, Gilead Sciences, Kite Pharma, and bluebird bio. These companies have launched several CAR T-cell therapy products, such as Kymriah, Yescarta, and Tecartus, which have shown promising results in clinical trials and have received regulatory approval for the treatment of various types of blood cancers. Thus, the market for Chimeric antigen receptor (CAR) T-cell therapy is expected to register a CAGR of 6.9% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market?
Growing demand for personalized and targeted therapies boosting the market growth
The increasing incidence of cancer worldwide is a major driver of the CAR T-cell therapy market. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, with an estimated 9.6 Billion deaths in 2018. CAR T-cell therapy has shown high success rates in clinical trials for the treatment of certain types of blood cancers, such as leukemia and lymphoma. The therapy has demonstrated durable responses and has shown the potential to cure some patients.
CAR T-cell therapy is a personalized and targeted therapy that is tailored to a patient's individual immune system and cancer cells. This approach has gained popularity in recent years as it can result in better outcomes and fewer side effects compared to traditional cancer treatments.
Several biotechnology and pharmaceutical companies are investing heavily in the research and development of CAR T-cell therapies. This has resulted in the development of innovative therapies and the expansion of the CAR T-cell therapy market.
The approval of CAR T-cell therapy products by regulatory agencies, such as the US FDA, has boosted market growth. Regulatory approval provides credibility to CAR T-cell therapy products, which can increase patient and physician acceptance of these therapies.
Active and continuous research and development driving CAR T- cell therapy market growth
CAR T-cell therapy has shown promising results in treating certain types of blood cancers, such as leukemia and lymphoma. However, it is a complex and expensive treatment that requires specialized medical centers with the expertise to perform it. The therapy can also cause severe side effects, including cytokine release syndrome and neurotoxicity, which require careful monitoring and management.
Several companies are actively involved in the development and commercialization of CAR T-cell therapies, including Novartis, Gilead Sciences, Kite Pharma, and bluebird bio. These companies have launched several CAR T-cell therapy products, such as Kymriah, Yescarta, and Tecartus, which have shown promising results in clinical trials and have received regulatory approval for the treatment of various types of blood cancers.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market?
The high cost of therapy along with limited availability creates obstacles to market growth
CAR T-cell therapy is a highly expensive treatment due to its complex manufacturing process and personalized nature. The high cost can limit patient access to therapy and can also impact healthcare system budgets. CAR T-cell therapy requires specialized medical centers with the expertise to perform the treatment, which can limit patient access to the therapy. Additionally, the therapy is only approved for the treatment of certain types of blood cancers, which limits its applicability to other cancer types.
CAR T-cell therapy can cause severe side effects, including cytokine release syndrome and neurotoxicity, which can be life-threatening. These side effects require careful monitoring and management, which can add to the overall cost of the therapy.
As the demand for CAR T-cell therapy grows, there is a shortage of manufacturing capacity to produce the therapy at scale. This shortage can limit the availability of the therapy and can also impact the cost of the therapy. The regulatory approval process for CAR T-cell therapy can be challenging and time-consuming. The regulatory agencies require extensive clinical data to support the safety and efficacy of the therapy, which can delay the approval process and increase the overall cost of development.
Region-Wise Insights
Increasing Demand for Personalized and Targeted Therapies Driving Growth Of (CAR) T-Cell Therapy Market in North America?
Availability of advanced healthcare infrastructure shaping landscape for (CAR) T-Cell therapy
North America is a significant market for Chimeric Antigen Receptor (CAR) T-Cell Therapy, with the USA being the largest market in the region. Several factors are driving the growth of the CAR T-cell therapy market in North America, including the high prevalence of cancer, the increasing demand for personalized and targeted therapies, and the availability of advanced healthcare infrastructure. In addition, several biotechnology and pharmaceutical companies in the region are actively involved in the research and development of CAR T-cell therapies, which is driving the growth of the market.
The USA is a key market for CAR T-cell therapy, with several CAR T-cell therapy products approved for the treatment of various types of blood cancers, such as Kymriah, Yescarta, and Breyanzi. The high cost of CAR T-cell therapy in the USA remains a challenge for the market, as it can limit patient access to the therapy. However, initiatives to improve insurance coverage and patient access to CAR T-cell therapy are underway, which is expected to support the growth of the market in the coming years. Thus, North America is expected to possess a 45% market share for (CAR) T-Cell Therapy in 2023.
Active Research and Development by Pharmaceutical Companies Shaping Landscape for (CAR) T-Cell Therapy Market in Europe?
Increasing demand for effective cancer treatments driving the growth of (the CAR) T-Cell market in Europe
Several factors are driving the growth of the CAR T-cell therapy market in Europe, including the increasing prevalence of cancer, the demand for personalized and targeted therapies, and the availability of advanced healthcare infrastructure. In addition, several biotechnology and pharmaceutical companies in Europe are actively involved in the research and development of CAR T-cell therapies, which is driving the growth of the market.
Several CAR T-cell therapy products have been approved for the treatment of various types of blood cancers in Europe, including Kymriah and Yescarta. The high cost of CAR T-cell therapy remains a challenge for the market in Europe, as it can limit patient access to the therapy. However, initiatives to improve patient access to CAR T-cell therapy are underway, which is expected to support the growth of the market in the coming years.
The European Medicines Agency (EMA) has established a framework for the approval of CAR T-cell therapy products, which is expected to streamline the regulatory process in the future. Overall, the Europe CAR T-cell therapy market is expected to continue to grow in the coming years, driven by the increasing demand for effective cancer treatments and the development of innovative CAR T-cell therapy products. Thus, Europe is expected to possess a 39% market share for (CAR) T-Cell Therapy in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
Effective and Promising Results of Yescarta Making It Popular for (CAR) T-Cell Therapy Market?
High rate of positive response contributing to increasing use of (CAR) T-Cell Therapy market
Yescarta is a type of CAR T-cell therapy that involves collecting a patient's T-cells and genetically modifying them in a laboratory to express a chimeric antigen receptor (CAR) that targets a protein called CD19, which is found on the surface of B-cells, including the cancerous B-cells that cause NHL. The modified T-cells are then infused back into the patient, where they seek out and destroy the cancer cells.
Yescarta has been shown to be effective in clinical trials, with high rates of complete response and durable remissions in patients with relapsed or refractory NHL. It is approved by the FDA for use in adults with certain types of NHL and is considered a promising option for patients who have exhausted other treatment options. Thus, by type, Yescarta is expected to possess a 45% market share for (CAR) T-Cell Therapy in 2023.
Market Competition
Key players in the chimeric antigen receptor (CAR) T-Cell therapy market are Abbott Laboratories, Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Fresenius SE & Co. KGaA, Johnson & Johnson, Medtronic PLC, Novartis AG, Endo International PLC, and Pfizer Inc.
Abbott Laboratories has contributed to CAR T-cell therapy by providing diagnostic tools to help identify patients who are suitable candidates for this treatment. For example, Abbott's Vysis CLL FISH Probe Kit is a diagnostic test that can be used to detect genetic abnormalities in chronic lymphocytic leukemia (CLL), a type of cancer that can be treated with CAR T-cell therapy. This test helps identify patients who have certain genetic mutations that make them more likely to respond to CAR T-cell therapy.
Baxter has contributed to CAR T-cell therapy by providing cell culture media and other materials needed for the manufacturing of CAR T-cell therapies. Baxter's Cell Culture Media and supplements are used in the laboratory to grow and expand the T-cells that will be used for CAR T-cell therapy. The company has also developed a closed system for the production of CAR T-cell therapies, which can help minimize contamination and improve the efficiency of the manufacturing process.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 3.5 billion
Market Value in 2033
US$ 6.82 billion
Growth Rate
CAGR of 6.9% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Type
Application
End User
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Key Countries Profiled
United States of America
Canada
Brazil
Mexico
Germany
United Kingdom
Spain
Germany
Italy
China
Japan
India
South Korea
South Africa
GCC Countries
Key Companies Profiled
Abbott Laboratories
Baxter International Inc.
Becton, Dickinson, and Company
Boston Scientific Corporation
Fresenius SE & Co. KGaA
Johnson & Johnson
Medtronic PLC
Novartis AG
Endo International PLC
Pfizer Inc.
Customization
Available Upon Request
Key Segments Profiled in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Survey
By Type:
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
Others
By Application:
Leukemia
Lymphoma
Multiple Myeloma
Autoimmune Disorders
Other Application
By End User:
Hospitals
Cancer Care Treatment Centers
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Frequently Asked Questions
What is the Size of the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market in 2023?
The market is valued at US$ 3.5 billion in 2023.
Who are the Leading Industry Participants?
Abbott Laboratories, Baxter International Inc., and Becton, Dickinson, and Company are the leading industry participants.
What is the Expected Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size?
The market is expected to reach US$ 6.82 billion by 2033.
What Factors are Driving the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market sales?
Rise in cancer cases is propelling the market's growth and development.
Which is the Key Segment by type in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market?
The yescarta segment is likely to remain preferred until 2033.
Table of Content
1. Executive Summary | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Abecma
5.3.2. Breyanzi
5.3.3. Kymriah
5.3.4. Tecartus
5.3.5. Yescarta
5.3.6. Others
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Leukemia
6.3.2. Lymphoma
6.3.3. Multiple Myeloma
6.3.4. Autoimmune Disorders
6.3.5. Other Application
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals
7.3.2. Cancer Care Treatment Centers
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States of America
9.2.1.2. Canada
9.2.2. By Type
9.2.3. By Application
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Application
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Type
10.2.3. By Application
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Application
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. United Kingdom
11.2.1.2. Spain
11.2.1.3. Germany
11.2.1.4. Italy
11.2.1.5. France
11.2.1.6. Rest of Europe
11.2.2. By Type
11.2.3. By Application
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Application
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. India
12.2.1.4. South Korea
12.2.1.5. Rest of Asia Pacific
12.2.2. By Type
12.2.3. By Application
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Application
12.3.4. By End User
12.4. Key Takeaways
13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. South Africa
13.2.1.2. GCC Countries
13.2.1.3. Rest of Middle East and Africa
13.2.2. By Type
13.2.3. By Application
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Application
13.3.4. By End User
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. United States of America
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Type
14.1.2.2. By Application
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Type
14.2.2.2. By Application
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Type
14.3.2.2. By Application
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Type
14.4.2.2. By Application
14.4.2.3. By End User
14.5. United Kingdom
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Type
14.5.2.2. By Application
14.5.2.3. By End User
14.6. Spain
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Type
14.6.2.2. By Application
14.6.2.3. By End User
14.7. Germany
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Type
14.7.2.2. By Application
14.7.2.3. By End User
14.8. Italy
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Type
14.8.2.2. By Application
14.8.2.3. By End User
14.9. France
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Type
14.9.2.2. By Application
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Type
14.10.2.2. By Application
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Type
14.11.2.2. By Application
14.11.2.3. By End User
14.12. India
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Type
14.12.2.2. By Application
14.12.2.3. By End User
14.13. South Korea
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Type
14.13.2.2. By Application
14.13.2.3. By End User
14.14. South Africa
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Type
14.14.2.2. By Application
14.14.2.3. By End User
14.15. GCC Countries
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Type
14.15.2.2. By Application
14.15.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Type
15.3.3. By Application
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Abbott Laboratories
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Baxter International Inc.
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Becton, Dickinson, and Company
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Boston Scientific Corporation
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Fresenius SE & Co. KGaA
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Johnson & Johnson
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Medtronic PLC
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Novartis AG
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Endo International PLC
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Pfizer Inc.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Asia Pacific Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 19: Asia Pacific Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 20: Asia Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 21: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 24: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Application, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 17: Global Market Attractiveness by Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Application, 2023 to 2033
Figure 19: Global Market Attractiveness by End User, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Application, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 37: North America Market Attractiveness by Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Application, 2023 to 2033
Figure 39: North America Market Attractiveness by End User, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Application, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Application, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Type, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Application, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 77: Europe Market Attractiveness by Type, 2023 to 2033
Figure 78: Europe Market Attractiveness by Application, 2023 to 2033
Figure 79: Europe Market Attractiveness by End User, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Asia Pacific Market Value (US$ Million) by Type, 2023 to 2033
Figure 82: Asia Pacific Market Value (US$ Million) by Application, 2023 to 2033
Figure 83: Asia Pacific Market Value (US$ Million) by End User, 2023 to 2033
Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 94: Asia Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 97: Asia Pacific Market Attractiveness by Type, 2023 to 2033
Figure 98: Asia Pacific Market Attractiveness by Application, 2023 to 2033
Figure 99: Asia Pacific Market Attractiveness by End User, 2023 to 2033
Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 101: Middle East and Africa Market Value (US$ Million) by Type, 2023 to 2033
Figure 102: Middle East and Africa Market Value (US$ Million) by Application, 2023 to 2033
Figure 103: Middle East and Africa Market Value (US$ Million) by End User, 2023 to 2033
Figure 104: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: Middle East and Africa Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 109: Middle East and Africa Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 110: Middle East and Africa Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 111: Middle East and Africa Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 112: Middle East and Africa Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 113: Middle East and Africa Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 114: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 115: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 116: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 117: Middle East and Africa Market Attractiveness by Type, 2023 to 2033
Figure 118: Middle East and Africa Market Attractiveness by Application, 2023 to 2033
Figure 119: Middle East and Africa Market Attractiveness by End User, 2023 to 2033
Figure 120: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
